New hope for Hard-to-Treat myeloma: targeted combo enters Late-Stage trial

NCT ID NCT06956170

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether a new combination of drugs—belantamab mafodotin, pomalidomide, and dexamethasone—works better than a standard combo for people with multiple myeloma that has returned or not responded to treatment. The study involves 21 Japanese adults who have already tried at least one prior therapy. Researchers will measure how long the cancer stays under control and watch for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belantamab mafodotin (a targeted antibody-drug conjugate) combined with pomalidomide and dexamethasone
What this could lead to: If successful, this could offer a new treatment option for people with multiple myeloma that has returned or not responded to prior therapy.
What could go wrong: This is a small, early-phase study in Japanese patients only, so results may not apply broadly. The drug combination may cause side effects like eye problems or low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

GSK Investigation Site

Fukushima, Fukushima, 960-1295, Japan
GSK Investigational Site

Nagoya, Aichi-ken, 467-8602, Japan
GSK Investigational Site

Kamogawa, Chiba, 296-8602, Japan
GSK Investigational Site

Kashiwa, Chiba, 277-8567, Japan
GSK Investigational Site

Matsuyama, Ehime, 790-8524, Japan
GSK Investigational Site

Maebashi, Gunma, 371-8511, Japan
GSK Investigational Site

Shibukawa, Gunma, 377-0280, Japan
GSK Investigational Site

Numakunai, Iwate, 028-3695, Japan
GSK Investigational Site

Okayama, Okayama-ken, 701-1192, Japan
GSK Investigational Site

Osaka, Osaka, 565-0871, Japan
GSK Investigational Site

Tottori-shi, Tottori, 683-8504, Japan
GSK Investigational Site

Yamagata, Yamagata, 990-9585, Japan
GSK Investigational Site

Hokkaido, 060-8648, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.